Less common but serious risks noted in prescribing information for GLP-1 medications include pancreatitis, gallbladder disease, and kidney injury in the setting of dehydration from gastrointestinal side effects
placebo in 3,127 adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, OSA, or cardiovascular disease, who did not have diabetes
Tirzepatide is a clinician-prescribed dual incretin receptor agonist designed to support appetite regulation and metabolic function via GLP-1 and GIP activity
This signalling divergence IGF-1R-independent ERK activation vs IGF-1R-dependent Akt/mTOR activation is one of the central research questions in the MGF field and is the mechanistic basis for the functionally distinct roles of MGF (proliferation, satellite cell activation, anti-differentiation) and mature IGF-1 (differentiation, protein synthesis, hypertrophy) in the sequential muscle regeneration programme
Related incretin-based medicines you might hear about include tirzepatide (Mounjaro for type 2 diabetes, and Zepbound for chronic weight management), a dual GIP/GLP-1 receptor agonist given as a once-weekly injection
